参考文献

［1］ SOAITA I, YIN W, RUBENSTEIN D A. Glycated albumin modifies platelet adhesion and aggregation responses [J]. Platelets, 2017, 28 (7): 682-690.

［2］ YANG X H, CAO R F, YU Y, et al. A study on the correlation between MTHFR promoter methylation and diabetic nephropathy [J]. Am J Transl Res, 2016, 8 (11): 4960-4967.

［3］ ZHANG L, ZHANG Q, LIU S, et al. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury [J]. Kidney Int, 2017, 92 (1): 140-153.

［4］ SHARMA D, BHATTACHARYA P, KALIA K, et al. Diabetic nephropathy: new insights into established therapeutic paradigms and novel molecular targets [J]. Diabetes Res Clin Pract, 2017, 128: 91-108.

［5］ KHAN S, JENA G, TIKOO K. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat [J]. Exp Mol Pathol, 2015, 98 (2): 230-239.

［6］ ALLISON S J. Diabetic nephropathy: A lncRNA and miRNA megacluster in diabetic nephropathy [J]. Nat Rev Nephrol, 2016, 12 (12): 713.

［7］ LI X, ZENG L, CAO C, et al. Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy [J]. Exp Cell Res, 2017, 350 (2): 327-335.

［8］ LONG J, BADAL S S, YE Z, et al. Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy [J]. J Clin Invest, 2016, 126 (11): 4205-4218.

［9］ YI H, PENG R, ZHANG L Y, et al. LincRNA-Gm4419 knockdown ameliorates NF-kappaB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy [J]. Cell Death Dis, 2017, 8 (2): e2583.

［10］ HU W, HAN Q, ZHAO L, et al. Circular RNA circRNA-15698 aggravates the extracellular matrix of diabetic nephropathy mesangial cells via miR-185/TGF-beta1 [J]. J Cell Physiol, 2019, 234 (2): 1469-1476.

［11］ GAO Y, CHEN Z Y, WANG Y, et al. Long non-coding RNA ASncmtRNA-2 is upregulated in diabetic kidneys and high glucose-treated mesangial cells [J]. Exp Ther Med, 2017, 13 (2): 581-587.

［12］ YU J, MAIMAITILI Y, XIE P, et al. High glucose concentration abrogates sevofLUrane post-conditioning cardioprotection by advancing mitochondrial fission but dynamin-related protein 1 inhibitor restores these effects [J]. Acta Physiol (Oxf), 2017, 220 (1): 83-98.

［13］ WANG W, WANG Y, LONG J, et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells [J]. Cell Metab, 2012, 15 (2): 186-200.

［14］ AYANGA BA, BADAL SS, WANG Y, et al. Dynamin-related protein 1 deficiency improves mitochondrial fitness and protects against progression of diabetic nephropathy [J]. J Am Soc Nephrol, 2016, 27 (9): 2733-2747.

［15］ PANDAY A, SAHOO M K, OSORIO D, et al. NADPH oxidases: an overview from structure to innate immunity-associated pathologies [J]. Cell Mol Immunol, 2015, 12 (1): 5-23.

［16］ GORIN Y, WAUQUIER F. Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease [J]. Mol Cells, 2015, 38 (4): 285-296.

［17］ GORIN Y, CAVAGLIERI R C, KHAZIM K, et al. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes [J]. Am J Physiol Renal Physiol, 2015, 308 (11): F1276-1287.

［18］ VAN J A, SCHOLEY J W, KONVALINKA A. Insights into diabetic kidney disease using urinary proteomics and bioinformatics [J]. J Am Soc Nephrol, 2017, 28 (4): 1050-1061.

［19］ PICHLER R, AFKARIAN M, DIETER BP, et al. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets [J]. Am J Physiol Renal Physiol, 2017, 312 (4): F716-f731.

［20］ SUN L, KANWAR Y S. Relevance of TNF-alpha in the context of other inflammatory cytokines in the progression of diabetic nephropathy [J]. Kidney Int, 2015, 88 (4): 662-665.

［21］ MESHKANI R, VAKILI S. Tissue resident macroph AGEs: Key players in the pathogenesis of type 2 diabetes and its complications [J]. Clin Chim Acta, 2016, 462: 77-89.

［22］ FEIGERLOVA E, BATTAGLIA-HSU S F. IL-6 signaling in diabetic nephropathy: From pathophysiology to therapeutic perspectives [J]. Cytokine Growth Factor Rev, 2017, 37: 57-65.

［23］ SANGOI MB, D E CARVALHO J A, TATSCH E, et al. Urinary inflammatory cytokines as indicators of kidney damage in type 2 diabetic patients [J]. Clin Chim Acta, 2016, 460: 178-183.

［24］ AL-LAMKI R S, MAYADAS T N. TNF receptors: signaling pathways and contribution to renal dysfunction [J]. Kidney Int, 2015, 87 (2): 281-296.

［25］ ROY M S, JANAL M N, CROSBY J, et al. Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes [J]. Kidney Int, 2015, 87 (2): 427-433.

［26］ SHI G J, SHI G R, ZHOU J Y, et al. Involvement of growth factors in diabetes mellitus and its complications: A general review [J]. Biomed Pharmacother, 2018, 101: 510-527.